Renalytix Plc Stock Deutsche Boerse AG
Equities
2O9
GB00BYWL4Y04
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.115 EUR | -4.17% |
|
-44.71% | -38.50% |
06-28 | ADRs Advance; Connect Biopharma Holdings Climbs 19% | DJ |
06-28 | EARNINGS AND TRADING: Thruvision loss widens but Polarean loss narrows | AN |
Sales 2024 * | 2.5M 2.34M 3.42M | Sales 2025 * | 6.98M 6.51M 9.54M | Capitalization | 21.46M 20.03M 29.35M |
---|---|---|---|---|---|
Net income 2024 * | -32M -29.88M -43.77M | Net income 2025 * | -24M -22.41M -32.82M | EV / Sales 2024 * | 8.58 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.08 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.53% |
Latest transcript on Renalytix Plc
1 day | -4.17% | ||
1 week | -44.71% | ||
Current month | -32.75% | ||
1 month | -44.71% | ||
3 months | -69.41% | ||
6 months | -19.58% | ||
Current year | -38.50% |
![Extreme 0.115](/images/extremecours_fleche.png)
![Extreme 0.115](/images/extremecours_fleche.png)
![Extreme 0.111](/images/extremecours_fleche.png)
![Extreme 0.111](/images/extremecours_fleche.png)
![Extreme 0.111](/images/extremecours_fleche.png)
![Extreme 0.111](/images/extremecours_fleche.png)
![Extreme 0.111](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
Howard Doran
PSD | President | 63 | 23-08-31 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Date | Price | Change |
---|---|---|
24-06-28 | 0.115 | -4.17% |
24-06-27 | 0.12 | -13.04% |
24-06-26 | 0.138 | -14.29% |
24-06-25 | 0.161 | -14.81% |
Delayed Quote Deutsche Boerse AG, June 28, 2024 at 09:29 am
More quotes![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.27% | 14.56B | |
-54.93% | 2.25B | |
+15.49% | 1.84B | |
-14.07% | 1.46B | |
+21.99% | 1.21B | |
-35.50% | 804M | |
+1.25% | 790M | |
-36.65% | 734M | |
-28.15% | 597M |
- Stock Market
- Equities
- RENX Stock
- 2O9 Stock